ES2178808T3 - Derivados omega-cicloalquil-prostaglandina e2. - Google Patents

Derivados omega-cicloalquil-prostaglandina e2.

Info

Publication number
ES2178808T3
ES2178808T3 ES98300769T ES98300769T ES2178808T3 ES 2178808 T3 ES2178808 T3 ES 2178808T3 ES 98300769 T ES98300769 T ES 98300769T ES 98300769 T ES98300769 T ES 98300769T ES 2178808 T3 ES2178808 T3 ES 2178808T3
Authority
ES
Spain
Prior art keywords
rent
group
halogen atom
same
prostaglandina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98300769T
Other languages
English (en)
Inventor
Kousuke Tani
Shuichi Ohuchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2178808T3 publication Critical patent/ES2178808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS OE -CICLOALQUILO DE LA PROSTAGLANDINA E 2 DE FORMULA (I): DONDE R ES UN GRUPO CARBOXI O HIDROMETILO; R SUP,1 ES UN GRUPO OXO, METILENO O UN ATOMO HALOGENO; R 2 ES H, OH O UN GRUPO C1-4 ALQUIOXILO; R 3 ES H, UN GRUPO C1-8 ALQUILO, C2-8 ALQUENILO, C2-8 ALQUINILO, C1-8 ALQUILO, C2-8 ALQUENILO O C2-8 ALQUINILO SUSTITUIDO POR 1.3 SUSTITUYENTES SELECCIONADOS ENTRE UN ATOMO HALOGENO, UN GRUPO C1-4 ALQUIOXILO, C3-7 CICLOALQUILO, FENILO, Y FENILO SUSTITUIDO POR 1-3 SUSTITUYENTES SELECCIONADOS ENTRE UN ATOMO HALOGENO, UN GRUPO C1-4 ALQUILO, C1-4 ALQUIOXILO, NITRO Y TRIFLUOROMETILO; N ES 0-4; Y SALES NO TOXICAS DE LOS MISMOS, PROFARMACOS DE LOS MISMOS Y CICLODEXTRINAS CLATRATOS DE LOS MISMOS UNIDOS FUERTEMENTE AL SUBTIPO EP 2 DEL RECEPTOR. POR TANTO, SON UTILES PARA LA PRE VENCION Y/O EL TRATAMIENTO DE ENFERMEDADES INMUNOLOGICAS (ENFERMEDADES AUTOINMUNES, TRASPLANTE DE ORGANOS, ETC.), ASMA, FORMACION ANORMAL DE HUESOS, MUERTE NEURONAL, LESION HEPATICA, ABORTO, NACIMIENTO PREMATURO O RETINOPATIA GLAUCOMATOSA, ETC.
ES98300769T 1997-02-04 1998-02-03 Derivados omega-cicloalquil-prostaglandina e2. Expired - Lifetime ES2178808T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3549997 1997-02-04
JP31916997 1997-11-06

Publications (1)

Publication Number Publication Date
ES2178808T3 true ES2178808T3 (es) 2003-01-01

Family

ID=26374500

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98300769T Expired - Lifetime ES2178808T3 (es) 1997-02-04 1998-02-03 Derivados omega-cicloalquil-prostaglandina e2.

Country Status (13)

Country Link
US (3) US6110969A (es)
EP (1) EP0860430B1 (es)
KR (1) KR100573535B1 (es)
AT (1) ATE219054T1 (es)
AU (1) AU736271B2 (es)
CA (1) CA2228828A1 (es)
DE (1) DE69805874T2 (es)
DK (1) DK0860430T3 (es)
ES (1) ES2178808T3 (es)
HU (1) HUP9800208A3 (es)
NO (1) NO317155B1 (es)
PT (1) PT860430E (es)
TW (1) TW581756B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE390917T1 (de) 1996-12-20 2008-04-15 Pfizer Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
WO2002009717A1 (fr) * 2000-07-31 2002-02-07 Ono Pharmaceutical Co., Ltd. Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
MXPA04004371A (es) * 2002-08-09 2004-08-13 Taisho Pharmaceutical Co Ltd Agente antipruritico.
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
ES2393321T3 (es) * 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
WO2004043471A1 (ja) * 2002-11-13 2004-05-27 Taisho Pharmaceutical Co., Ltd. 鎮痒剤
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
JPWO2004089411A1 (ja) * 2003-04-03 2006-07-06 小野薬品工業株式会社 脊柱管狭窄症治療剤
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
RU2420316C2 (ru) 2005-06-03 2011-06-10 Оно Фармасьютикал Ко., Лтд. Агент для регенерации и/или защиты нервов
US7563924B2 (en) * 2005-11-21 2009-07-21 Schering Aktiengesellschaft 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
US7737145B2 (en) 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
AU2007307638A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
ATE545416T1 (de) 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc Verwendung von spiro-oxindol-verbindungen als therapeutika
EP2094273B1 (en) 2006-11-16 2013-03-06 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
NZ712378A (en) 2009-10-14 2017-05-26 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
EP2538919B1 (en) 2010-02-26 2017-07-12 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2740724B1 (en) * 2011-08-05 2016-12-28 ONO Pharmaceutical Co., Ltd. Compound for treating cartilage disorders
AU2012299218A1 (en) 2011-08-19 2014-02-20 Merck Sharp & Dohme Corp. Crystal forms of a HCV protease inhibitor
RU2474426C1 (ru) * 2011-12-26 2013-02-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Простамиды и их аналоги, обладающие нейрозащитным действием
CA2869547A1 (en) 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP2818484A1 (en) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CA3045954A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
EP3551608A1 (en) 2016-12-09 2019-10-16 Celtaxsys Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
WO2018107153A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061670A (en) * 1976-07-19 1977-12-06 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
US4336404A (en) * 1979-05-14 1982-06-22 Miles Laboratories, Inc. 1-Acyloxy-15-deoxy-16-hydroxy-analogs of prostaglandin E1
US4363817A (en) * 1981-08-27 1982-12-14 Miles Laboratories, Inc. Enol acylate analogs of E1 and E2 prostaglandins
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
EP0860430A3 (en) 1999-06-23
TW581756B (en) 2004-04-01
DK0860430T3 (da) 2002-09-09
EP0860430A2 (en) 1998-08-26
KR100573535B1 (ko) 2006-12-15
HUP9800208A3 (en) 2000-04-28
HU9800208D0 (en) 1998-03-30
NO980442L (no) 1998-08-05
EP0860430B1 (en) 2002-06-12
PT860430E (pt) 2002-11-29
DE69805874D1 (de) 2002-07-18
CA2228828A1 (en) 1998-08-04
AU5289298A (en) 1998-08-06
HUP9800208A2 (hu) 1998-09-28
NO317155B1 (no) 2004-08-30
US20030186939A1 (en) 2003-10-02
US6576785B1 (en) 2003-06-10
NO980442D0 (no) 1998-02-02
US6110969A (en) 2000-08-29
KR19980071021A (ko) 1998-10-26
DE69805874T2 (de) 2002-12-19
AU736271B2 (en) 2001-07-26
ATE219054T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
ES2178808T3 (es) Derivados omega-cicloalquil-prostaglandina e2.
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2182220T3 (es) Derivados de acido 3,7-ditiaprostanoico.
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
BR9811774A (pt) Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
ES2178352T3 (es) Derivados de omega-cicloaquil-prostaglandina e1.
ES2152444T3 (es) Derivados de acido benzazepin-, benzoxazepin- y benzotiazepin-n-acetico, asi como procedimiento para su preparacion y medicamentos que contienen a estos compuestos.
ES2190458T3 (es) Empleo de dioxomorfolinas para la lucha contra los endoparasitos, nuevas dioxomorfolinas y procedimientos para su obtencion.
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
PE44597A1 (es) Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
AR007135A1 (es) Compuestos de benzofurano y benzopirano, formulaciones farmaceuticas que los contienen y metodos para preparar los compuestos y las formulaciones
AR004158A1 (es) Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.
AR035739A1 (es) Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
ES2090081T3 (es) Derivados de indolocarbazol, procedimientos para su obtencion y su empleo.
BR0307783A (pt) Composições e métodos para tratar doenças do tecido epitelial e retinal
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
ES2151716T3 (es) Derivados peptidos.
ES2181927T3 (es) Derivados de 1-metilcarbapenem.